Thomas Edison

EDISON INTERNATIONAL INVESTIGATION ALERT REMINDER: Scott+Scott Attorneys at Law LLP Investigates Edison International’s Directors and Officers For Breach of Fiduciary Duties – EIX

Retrieved on:

Tuesday, July 5, 2022 - 11:40pm

GLOBE, Foundation, Edison International, NYSE, Law, Management, Thomas Edison, Southern California Edison

NEW YORK, July 05, 2022 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (Scott+Scott), a national securities and consumer rights litigation firm, reminds investors it is investigating whether certain directors and officers of Edison International (Edison) (NYSE: EIX) breached their fiduciary duties to Edison and its shareholders.

Key Points:

NEW YORK, July 05, 2022 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (Scott+Scott), a national securities and consumer rights litigation firm, reminds investors it is investigating whether certain directors and officers of Edison International (Edison) (NYSE: EIX) breached their fiduciary duties to Edison and its shareholders.
If you are an Edison shareholder, you are encouraged to contact attorney Joe Pettigrew for additional information at (844) 818-6982, or jpettigrew@scott-scott.com .
Scott+Scott is investigating whether members of Edisons board of directors or senior management failed to manage Edison in an acceptable manner, in breach of their fiduciary duties to Edison, and whether Edison and its shareholders have suffered damages as a result.
If you are an Edison shareholder, you may have legal claims against Edisons directors and officers.

Edison Investment Research Limited: Induction Healthcare Group (INHC) initiation – Evolving technology in healthcare

Retrieved on:

Tuesday, July 5, 2022 - 8:02am

EBITDA, Growth, Patient, Health care, Research, Attend Anywhere, Financial services, Thomas Edison

Induction Healthcare is a growing UK-based healthcare software company, aiming to provide patients with more flexible care options beyond the traditional face-to-face consultation model.

Key Points:

Induction Healthcare is a growing UK-based healthcare software company, aiming to provide patients with more flexible care options beyond the traditional face-to-face consultation model.
Our forecasts indicate further growth in revenue and profitability, which should be supported by its robust cash position.
Click here to view the full report or here to sign up to receive research as it is published.
About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors.

Edison Interactive Welcomes Jim Grice as Vice President of Corporate Partnerships and Kevin Daly as Director of Hospitality Sales

Retrieved on:

Wednesday, June 29, 2022 - 4:13pm

DENVER, June 29, 2022 /PRNewswire/ -- Today Edison Interactive, a leading content management system for connected devices, announced the addition of Jim Grice, VP of Corporate Partnerships, and Kevin Daly, Director of Hospitality Sales, to the team. The two bring extensive experience to the organization and will be instrumental in heading up the sales initiatives for Edison's in-room entertainment solution, Edison TV.

Key Points:

DENVER, June 29, 2022 /PRNewswire/ -- Today Edison Interactive , a leading content management system for connected devices, announced the addition of Jim Grice, VP of Corporate Partnerships, and Kevin Daly, Director of Hospitality Sales, to the team.
At Edison, Grice will be responsible for leading and expanding the organization's internal sales team, driving revenue and supporting the go-to-market strategy.
Daly, previously the Director of Franchise Development for Wyndham Hotels, was responsible for selling franchises for 15 different hotel brands and driving new business.
In his role at Edison, Daly will work closely with Grice to expand Edison TV across hospitality brands everywhere.

Tetragon Financial Group (TFG): Offering a diverse exposure to alternative assets

Retrieved on:

Wednesday, June 29, 2022 - 11:05am

Research, NAV, Sale, Tetragon Financial Group, Investment, LTM, LCM, Intention, Financial services, Thomas Edison, Quadrilateral

Tetragon Financial Group (Tetragon) focuses on alternative asset classes offering excess risk-adjusted returns (ie intrinsic alpha).

Key Points:

Tetragon Financial Group (Tetragon) focuses on alternative asset classes offering excess risk-adjusted returns (ie intrinsic alpha).
This includes private equity holdings in alternative asset managers, investments in funds, as well as balance sheet investments in alternative assets.
Tetragon posted a 14.1% NAV total return in FY21 in US dollar terms and so far saw only an 0.6% NAV decline in 2022 until end-April.
About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors.

EDISON INTERNATIONAL INVESTIGATION REMINDER: Scott+Scott Attorneys at Law LLP Investigates Edison International’s Directors and Officers For Breach of Fiduciary Duties – EIX

Retrieved on:

Thursday, June 23, 2022 - 10:50pm

Legal, Professional Services, NYSE, Edison International, Foundation, Law, Management, Southern California Edison, Thomas Edison

Scott+Scott Attorneys at Law LLP (Scott+Scott), a national securities and consumer rights litigation firm, reminds investors it is investigating whether certain directors and officers of Edison International (Edison) (NYSE: EIX) breached their fiduciary duties to Edison and its shareholders.

Key Points:

Scott+Scott Attorneys at Law LLP (Scott+Scott), a national securities and consumer rights litigation firm, reminds investors it is investigating whether certain directors and officers of Edison International (Edison) (NYSE: EIX) breached their fiduciary duties to Edison and its shareholders.
If you are an Edison shareholder, you are encouraged to contact attorney Joe Pettigrew for additional information at (844) 818-6982, or jpettigrew@scott-scott.com .
Scott+Scott is investigating whether members of Edisons board of directors or senior management failed to manage Edison in an acceptable manner, in breach of their fiduciary duties to Edison, and whether Edison and its shareholders have suffered damages as a result.
If you are an Edison shareholder, you may have legal claims against Edisons directors and officers.

Edison Investment Research Limited: Scandion Oncology (SCOL): Initiation - Chemotherapy overcoming drug resistance

Retrieved on:

Tuesday, June 21, 2022 - 7:02am

FOLFIRI, Oncology, Phases of clinical research, Phase, Research, Pancreatic cancer, Oil, Thomas Edison

Scandion Oncology is a Danish biotechnology company that specialises in developing drugs to reverse chemotherapy resistance.

Key Points:

Scandion Oncology is a Danish biotechnology company that specialises in developing drugs to reverse chemotherapy resistance.
Managements clinical programme is spearheaded by the Phase II CORIST study in FOLFIRI-resistant mCRC, from which we expect crucial proof-of-concept results in Q322.
Click here to view the full report or here to sign up to receive research as it is published.
About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors.

Edison Investment Research Limited: Picton Property Income (PCTN): Record FY22 with positive outlook

Retrieved on:

Tuesday, June 21, 2022 - 7:02am

Growth, DPS, Property, Research, Financial services, Thomas Edison

Picton Property Incomes FY22 total earnings of 147m were the strongest since the company launched in 2005.

Key Points:

Picton Property Incomes FY22 total earnings of 147m were the strongest since the company launched in 2005.
Income gains and normalised rent collection underpinned DPS growth and while strong valuation uplifts mirrored broad market trends, Picton continued to build on its long-term record of portfolio outperformance.
Returns are likely to moderate from the exceptional level of FY22, but Picton remains positive despite global economic and political challenges.
About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors.

GE Healthcare Introduces Wireless Patient Monitoring Solution to Help Clinicians Detect Early Patient Deterioration

Retrieved on:

Monday, June 20, 2022 - 8:00am

With most hospitals around the world currently relying on manual spot-checks to monitor patient vitals, GE Healthcare unveils Portrait Mobile3, a wireless patient monitoring system that enables continuous monitoring throughout a patients stay.

Key Points:

With most hospitals around the world currently relying on manual spot-checks to monitor patient vitals, GE Healthcare unveils Portrait Mobile3, a wireless patient monitoring system that enables continuous monitoring throughout a patients stay.
Early detection of patient deterioration may help reduce length of stay and intensive care unit (ICU) admissions and improve patient outcomes4.
Patient mobility may help improve patient outcomes and reduce length of stay, which may lower costs and elevate patient satisfaction10.
GE Healthcare is the $17.7 billion healthcare business of GE (NYSE: GE).

EDISON INTERATIONAL INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates Edison International’s Directors and Officers For Breach of Fiduciary Duties – EIX

Retrieved on:

Thursday, June 16, 2022 - 5:18pm

GLOBE, Law, Edison International, NYSE, Foundation, Management, Southern California Edison, Thomas Edison

NEW YORK, June 16, 2022 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (Scott+Scott), a national securities and consumer rights litigation firm, is investigating whether certain directors and officers of Edison International (Edison) (NYSE: EIX) breached their fiduciary duties to Edison and its shareholders.

Key Points:

NEW YORK, June 16, 2022 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (Scott+Scott), a national securities and consumer rights litigation firm, is investigating whether certain directors and officers of Edison International (Edison) (NYSE: EIX) breached their fiduciary duties to Edison and its shareholders.
If you are an Edison shareholder, you are encouraged to contact attorney Joe Pettigrew for additional information at (844) 818-6982, or jpettigrew@scott-scott.com .
Scott+Scott is investigating whether members of Edisons board of directors or senior management failed to manage Edison in an acceptable manner, in breach of their fiduciary duties to Edison, and whether Edison and its shareholders have suffered damages as a result.
If you are an Edison shareholder, you may have legal claims against Edisons directors and officers.

Thailand Becomes First Asian Country to Legalize Marijuana

Retrieved on:

Thursday, June 16, 2022 - 1:50pm

NEW YORK, June 16, 2022 /PRNewswire/ -- Thailand made headlines last week when it became the first country in Asia to decriminalize marijuana, making it legal to grow and sell or use for medicinal reasons. Thai Health Minister Anutin Charnvirakul expects legal cannabis production to boost the economy, but warned that recreational cannabis use remains illegal. The public health minister also launched a plan to distribute 1 million marijuana seedlings with a THC level below 0.2% to households across Thailand for medicinal purposes. Cannabis decriminalization in Thailand opens up a new market for cannabis companies like Flora Growth Corp. (NASDAQ: FLGC), OrganiGram Holdings Inc. (NASDAQ: OGI) (TSX:OGI), Cronos Group (NASDAQ: CRON) (TSX: CRON), Canopy Growth Corp. (TSX: WEED) (NASDAQ: CGC), and Zynerba Pharmaceuticals (NASDAQ: ZYNE).

Key Points:

NEW YORK, June 16, 2022 /PRNewswire/ -- Thailand made headlines last week when it became the first country in Asia to decriminalize marijuana, making it legal to grow and sell or use for medicinal reasons.
The public health minister also launched a plan to distribute 1 million marijuana seedlings with a THC level below 0.2% to households across Thailand for medicinal purposes.
Created by Dr. Annabelle and backed by her research, Masaya's pure and potent CBD oil formulations are 100% THC-free.
Masaya will become a Flora-owned brand sold in the United States and will be Flora Life Sciences' first offering.